[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: Volume 22, Issue 2 (4-2024) ::
Int J Radiat Res 2024, 22(2): 449-455 Back to browse issues page
Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors
Y. Chen , S. Chen , Y. Li , X. Guo , Q. Liang , L. Yang , C. Lei
Department of Respiratory and Critical Care Medicine, The Second Clinical Medical College of North Sichuan Medical College, Nanchong Central Hospital, Nanchong, Sichuan 637000, China , 13990829946@163.com
Abstract:   (103 Views)
Background: The To measure regulatory T cells (Tregs) expression in driver-gene-negative advanced non-small cell lung cancer (NSCLC) as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors (ICIs). Materials and Methods: Fifty patients with advanced non-small cell lung cancer without driving genes who were receiving treatment with a monoclonal antibody targeting the programmed death receptor-1 (PD-1) made up the study group. 30 healthy subjects in the same period were chosen into the control group. Flow cytometry was used to identify CD4highCD25+Foxp3+Treg cells in peripheral blood of all participants. Relation between CD4highCD25+Foxp3+Treg cells and tumor markers were explored, and efficacy and prognosis in patients before and after therapy was analyzed. Results: The fraction of CD4highCD25+Foxp3+Treg cells in the study group was higher (P<0.05). Following three rounds of PD-1 monoclonal antibody treatment, patients' CD4highCD25+Foxp3+Treg cells proportion was lower than before treatment (P<0.01), and showed a positive correlation with tumor markers (P<0.05). The fraction of CD4highCD25+Foxp3+Treg cells in the CR+PR group decreased in both the second and third cycles after treatment compared to the SD+PD group (P<0.01), but no change was found before or during the first cycle (P>0.05). CD4highCD25+Foxp3+Treg cells proportion in the death group presented higher relative to the survival group (P<0.05). CD4highCD25+Foxp3+Treg cells predicted the area under the ROC curve was 0.8134, with significant difference (P<0.05). Conclusion: CD4highCD25+Foxp3+Treg cells proportion in peripheral blood of NSCLC patients shows increased, and has predictive value for therapeutic efficacy of ICIs and prognosis of driver-gene-negative advanced NSCLC patients.
Keywords: Non-small cell lung cancer, regulatory T cells, immune checkpoint inhibitors, prognosis.
Full-Text [PDF 596 kb]   (17 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Chen Y, Chen S, Li Y, Guo X, Liang Q, L. Yang et al . Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors. Int J Radiat Res 2024; 22 (2) :449-455
URL: http://ijrr.com/article-1-5468-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 22, Issue 2 (4-2024) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.05 seconds with 50 queries by YEKTAWEB 4652